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Purpose: To determine the element that modulates benzalkonium chloride (BAC) toxicity by using a 
new electrophysiological method to evaluate acute corneal barrier dysfunction induced by travoprost 
Z with sofZia (Travatan Z), travoprost with 0.015% BAC (Travatan), and its additives. 
Methods: Corneal transepithelial electrical resistance (TER) was measured in live white Japanese 
rabbits by two Ag/AgCl electrodes placed in the anterior aqueous chamber and on the cornea. We 
evaluated corneal TER changes after a 60-s exposure to travoprost Z, travoprost, and 0.015% BAC. 
Similarly, TER changes were evaluated after corneas were exposed for 60 s to the travoprost 
additives EDTA, boric acid, mannitol, trometamol, and polyoxyethylene hydrogenated castor oil 40 
(HCO-40) with or without BAC. Corneal damage was examined after exposure to BAC with or 
without travoprost additives using scanning electron microscopy (SEM) and a cytotoxicity assay. 
Results: Although no decreases of TER were noted after exposure to travoprost Z with sofZia and 
travoprost with 0.015% BAC, a significant decrease of corneal TER was observed after 0.015% 
BAC exposure. With the exception of for BAC, no corneal TER decreases were observed for any 
travoprost additives. After corneal exposure to travoprost additives with BAC, HCO-40 was able to 
prevent the BAC-induced TER decrease. SEM observations and the cytotoxicity assay confirmed 
that there was a remarkable improvement of BAC-induced corneal epithelial toxicity after addition 
of HCO-40 to the BAC. 
3 
 
Conclusions: Travoprost Z with sofZia and travoprost with BAC do not induce acute corneal barrier 




Benzalkonium chloride (BAC) is the most commonly used antimicrobial preservative in topical 
eyedrops because of its efficiency, stability, and solubility. BAC is a quaternary ammonium cationic 
surfactant that disrupts the bacterial cell membranes. In addition, it also enhances corneal barrier 
penetration. On the other hand, numerous in vitro, ex vivo, and in vivo studies have revealed the 
deleterious corneal effects of BAC that include destabilization of the tear film,1 death of corneal 
epithelium cells,2,3 disruption of superficial cell membranes, loss of microvilli4-7 and the reduction of 
the corneal epithelial barrier function.8 The side effects of BAC depend both on its concentration and 
the period of exposure. Chronic topical administration of BAC in rabbit eyes induces dry eye 
syndrome with damage to the cornea and the conjunctiva.9 Eyedrops containing BAC administrated 
to the human corneal surface also induce pre-corneal tear film instability and corneal epithelial 
barrier dysfunction.10 
Glaucoma is a chronic progressive optic neuropathy that requires long-term treatment with topical 
medications. Many classes of eyedrops are currently used to treat glaucoma, including cholinergic 
agents, beta-blockers, alpha-adrenergic agonists, carbonic anhydrase inhibitors, and prostaglandin 
analogs. Among these eyedrops, prostaglandin analogs occupy the center stage and are considered to 
be the first-line medications.11 The four different prostaglandin analogs that are currently available 
for the treatment of glaucoma include latanoprost, travoprost, bimatoprost, and tafluprost. The 
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formulations of each of these also contain BAC, with levels that range from 0.005% to 0.02%. 
Previous studies in glaucoma patients have demonstrated that the use of eyedrops containing BAC 
may affect the vision-related quality of life12 and that chronic use of eyedrops containing BAC can 
reduce the success of glaucoma filtration surgery.13-16 Therefore, the general consensus today is that 
chronic use of prostaglandin analogs that contain BAC has the potential to cause adverse corneal 
effects. 
There are two kinds of travoprost ophthalmic solutions: travoprost Z, which uses the sofZia 
preservative (Travatan Z, Alcon, Inc., Fort Worth, TX, USA), and travoprost, which is preserved 
using 0.015% BAC (Travatan, Alcon). Travoprost Z uses the newly developed sofZia, which is a 
non-BAC preservative system that was created in order to prevent the BAC-caused ocular surface 
side effects. An in vitro study that used conjunctiva-derived epithelial cells has shown that travoprost 
Z has a significantly lower cytotoxicity and pro-apoptotic effect as compared to travoprost.17 To date, 
however, there have been no reports that have compared acute corneal impairment after exposure to 
travoprost Z and travoprost in vivo. 
On the other hand, we have already developed a new in vivo method for measuring the 
transepithelial electrical resistance (TER) of live rabbit corneas.18 This novel approach for examining 
the clinical instillation of eyedrops has revealed that exposure to BAC concentrations between 
0.005%-0.02% immediately causes acute corneal dysfunction.19, 20 In our preliminary experiments, 
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we found that travoprost caused low acute corneal impairment regardless of whether it contained 
0.015% BAC. Therefore, we decided to further examine this phenomenon by electrophysiologically 
comparing the acute corneal barrier dysfunction induced by travoprost Z, travoprost, and 0.015% 




Materials and Methods 
Chemicals 
Two kinds of travoprost ophthalmic solutions, travoprost Z (Travatan Z) and travoprost 
(Travatan) were obtained from Alcon. Benzalkonium chloride 10% solution and trometamol were 
purchased from Wako Pure Chemical Co. (Osaka, Japan). Boric acid and mannitol were obtained 
from Nacalai Tesque, Inc. (Kyoto, Japan) and Sigma-Aldrich Japan Co. (Tokyo, Japan), respectively. 
Polyoxyethylene hydrogenated castor oil 40 (HCO-40) was purchased from Nikko Chemicals Co. 
(Tokyo, Japan). Ethylenediaminetetraacetic acid disodium salt (EDTA), 
2-(4-lodophenyl)-3-(4-nitrophenyl)-2H-tetrazolium, monosodium salt (WST-1), and 
1-methoxy-5-methylphenazinium methylsulfate (1-methoxy PMS) were obtained from Dojindo 
Laboratories, Inc. (Kumamoto, Japan). Hank’s balanced salt Ca2+ and Mg2+ free solution (HBSS) 
were purchased from Invitrogen Corp. (Carlsbad, CA, USA). Rabbit corneal epithelial cell growth 
medium (RCGM) and culture reagents were obtained from Kurabo Co., Ltd. (Osaka, Japan). Test 
solutions such as 0.02% BAC, 0.1% EDTA, 2% boric acid, 2% mannitol, 0.5% trometamol, and 1% 
HCO-40 were prepared in HBSS or RCGM. The concentrations for each of the agents were set at 






Male white Japanese rabbits (KBT Oriental, Tosu, Japan) weighing 2.5-3.0 kg were individually 
housed in cages under a controlled temperature (21°C) and humidity (50  5%) and a 12:12 h 
light/dark cycle at the Laboratory Animal Center for Biomedical Research, Nagasaki University 
School of Medicine. Initiation of the study occurred once the rabbits reached weights of 3.0-4.0 kg, 
as this was the point where corneal diameters were of a suitable size for experimentation. The rabbits 




The rabbits were anesthetized with an intramuscular injection of 30 mg/kg ketamine (Ketalar, 
Sankyo, Tokyo, Japan) and 5 mg/kg xylazine (Celactal, Bayer Health Care, Osaka, Japan). The 
experimental procedure was started within 10 min of the induction of anesthesia. After a slit lamp 
examination of the eyes to confirm that the cornea was intact, adhesive tape was applied so that one 
eye was kept open while the other eye was kept closed. 
After a small incision was made with an 18-gauge sharp needle (Terumo, Tokyo, Japan) in the 
peripheral cornea, a 1.0-mm diameter custom-made Ag/AgCl electrode (Physiotech, Tokyo, Japan) 
was inserted into the anterior chamber. A 6.0-mm internal diameter (0.28 cm2 inner area) nitrile 
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rubber O-ring (Union Packing, SAN-EI, Osaka, Japan) was fixed on the cornea using biomedical 
adhesive (Alon-Alpha A, Sankyo, Tokyo, Japan). Subsequently, 80 L of HBSS was placed inside 
the ring, with the second electrode then placed in HBSS on the cornea. This initial procedure was 
carefully conducted in order to avoid damaging the center of the cornea. The specific methodology 
and photographs of the in vivo corneal TER measurement system have been previously published 
[18]. 
The TER was measured in real time using a volt-ohm meter (EVOMX, World Precision 
Instruments, Sarasota FL, USA) that generated a 20 µA AC square wave current at 12.5 Hz. Data 
were recorded using a thermal array recorder (WR300-8, Graphtec, Tokyo, Japan). In a period of just 
a few seconds, 1 mL of either the eyedrops or the test solutions was gently poured into the ring, with 
all of the overflow being aspirated. After an exposure period of 60 s, the rings were washed out 
using 1 mL of HBSS. After obtaining the TER of the cornea before and after the exposure, results 
were then calculated as a percentage of the pre-exposure TER value (100%). 
 
Scanning electron microscopy (SEM) observation 
The rabbits were anesthetized with an intramuscular injection of 30 mg/kg ketamine and 5 mg/kg 
xylazine. All corneas were evenly soaked in each of the test solutions for 60 s, with HBSS used to 
wash out the corneas. After the corneal washing, the rabbits were immediately sacrificed using a 
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lethal dose of intravenous sodium pentobarbital (Nembutal, Dainippon Pharmaceutical, Osaka, 
Japan). The corneas were carefully excised, fixed in 4% glutaraldehyde in 0.05 M cacodylate buffer 
for 1 h and then post-fixed in 1% osmium tetroxide in veronal acetate buffer containing 0.22 M 
sucrose. The fixed materials were dehydrated through a series of ethanol washes. Corneas were 
placed in t-butyl alcohol after being treated in a freeze-drying apparatus (EIKO ID-2, EIKO, Tokyo, 
Japan), spatter coated with gold using an auto fine coater (JEOL JFC-1600, JEOL, Tokyo, Japan) 
and then examined using a scanning electron microscope (Hitachi S2360, Hitachi, Tokyo, Japan). 
 
Cytotoxicity assay 
The normal rabbit corneal epithelial (NRCE) cells were obtained from Kurabo Co., Ltd. (Osaka, 
Japan). The NRCE cells were maintained in RCGM, which was supplemented with 5 µg/mL insulin, 
10 ng/mL epidermal growth factor, 0.5 µg/mL hydrocortisone, 50 µg/mL gentamicin, 50 ng/mL 
amphotericin B, and 0.4% bovine pituitary extractives reagent. The cells were grown at 37°C in a 
humidified atmosphere with 5% CO2. Cytotoxicity tests on NRCE cells were carried out using a 
WST-1 commercially available cell proliferation reagent. The assay was based on cleavage of the 
tetrazolium salt WST-1 by active mitochondria to produce a soluble colored formazan salt. Since the 
conversion can only occur with viable cells, results are directly correlated to the cell number. The 
stock solutions of WST-1 (5.5 mM) and 1-methoxy PMS (2 mM) were prepared in sterilized 
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phosphate-buffered saline. Just prior to each of the experiments, the mixture was prepared by 
combining 0.9 mL of WST-1 solution and 0.1 mL of 1-methoxy PMS solution. NRCE cells were 
plated at 3  103 cells/well in 96-well microtiter plates (Becton-Dickinson, Franklin, NJ, USA). Six 
days after plating, the growth medium was replaced with 100 µL of the test solutions for 60 s. The 
cells were washed with fresh growth medium, and then 100 µL of fresh growth medium and 10 µL 
of WST-1 mixture solution were added to each well. After incubation of the cells for 3 h at 37°C, a 
microplate reader (Thermo Fisher Scientific. Inc., Waltham, MA, USA) was used to measure the 
absorbance at a wavelength of 450 nm, with a reference wavelength of 630 nm. The results are 
presented as a percentage of the untreated cells. 
 
Evaluation of physicochemical properties 
The zeta potential was measured for the surface charge of the particles. Zeta potential is defined 
as the potential difference between the dispersion medium and the stationary layer of fluid that is 
attached to the dispersed particle. The particle size and zeta potential for each agent were measured 
using the Zetasizer Nano ZS (Malvern Instruments, Ltd., Malvern, Worcestershire, UK). 
Measurements were performed 13 and 15 times for the particle size and the zeta potential, 





The results were expressed as the mean  standard error of at least three experiments. Statistical 
comparisons were performed by analysis of variance (ANOVA) followed by a Tukey-Kramer test for 
the TER measurement and cytotoxicity assay. A Student’s t-test was used to analyze the 





Corneal exposure to travoprost Z, travoprost, and 0.015% BAC 
The mean corneal TER for the live rabbits used in this study was 701.6  43.1 ·cm2 (52 eyes). 
Figure 1 shows the TER changes that occurred after corneal exposure to HBSS, travoprost Z, 
travoprost, and 0.015% BAC. While there was no change in the corneal TER after exposure to HBSS 
or to the travoprost Z, which did not contain BAC, a significant decrease of the corneal TER was 
observed after the exposure to 0.015% BAC. However, no decrease in the TER was observed after 
corneal exposure to travoprost, regardless of whether it contained 0.015% BAC. 
 
Corneal exposure to travoprost additives with or without 0.02% BAC 
The concentration of BAC was set at 0.02% in the subsequent experiments, as this is the highest 
concentration that is normally applied in commercial eyedrops. The influence of the travoprost 
additives on the TER changes was analyzed by examining each additive in the presence and absence 
of 0.02% BAC (Fig. 2). Data for the negative and positive controls were obtained by exposing the 
cornea to only HBSS or to BAC, respectively. As shown in Fig. 2A, there were no corneal TER 
changes noted for any of the additives. While mixing HCO-40 with BAC prevented BAC-induced 
corneal barrier dysfunction, EDTA, boric acid, mannitol, and trometamol were not able to modulate 
BAC toxicity (Fig. 2B). 
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Scanning electron microscopy observation 
After exposure to HBSS, the SEM images in the control corneal epithelium exhibited a normal 
appearance of superficial cells with a high density of microvilli (Fig. 3). However, after exposure to 
0.02% BAC, there was detaching and wrinkling of the superficial cells, dissociations between the 
cells, and degenerated microvilli observed in the corneal epithelium (Fig. 4). Conversely, no damage 
to the corneal epithelium was observed after it was exposed to a solution of 0.02% BAC and 1% 
HCO-40 (Fig. 5). 
 
Cytotoxicity assay 
Cytotoxicity of the travoprost additives on the NRCE cells was examined by a WST-1 assay in the 
presence and absence of 0.02% BAC (Fig. 6). Exposure to BAC by itself was used as the positive 
control. As shown in Fig. 6A, none of the additives caused any significant decrease in the cell 
viability as compared with untreated cells (control). While mixing HCO-40 with BAC decreased the 
cytotoxicity of the BAC, EDTA, boric acid, mannitol, and trometamol did not prevent the 
cytotoxicity (Fig. 6B). 
 
Physicochemical properties of BAC, HCO-40, and HCO-40 with BAC 
In order to elucidate the modulation mechanism of HCO-40, the particle size and zeta potential of 
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either 0.02% BAC alone or 1% HCO-40 solution with or without 0.02% BAC were measured (Table 
1). The particle size and zeta potential of 0.02% BAC could not be detected. With 1% HCO-40, 
which forms a dispersion, the mean particle size was 25.7 nm and the mean zeta potential was -0.8 
mV. On the other hand, after adding 0.02% BAC to 1% HCO-40, the particle size decreased from 




Most commercially available prostaglandin analogs contain BAC, which is associated with ocular 
surface side effects. Currently, new prostaglandin analog formulations that do not contain BAC are 
being developed. In one of these new agents, travoprost Z, BAC has been replaced with sofZia, 
which is a non-BAC preservative system that contains boric acid, sorbitol, propylene glycol, and 
zinc chloride. Several comparative studies of ocular surface changes induced by prostaglandin 
analogs have shown that travoprost Z causes significantly less corneal and conjunctival toxicity as 
compared to the latanoprost ophthalmic solution that contains 0.02% BAC.21-24 In these reports, 
however, comparisons of travoprost Z with travoprost were not performed. Therefore, we decided to 
evaluate the corneal toxicity of travoprost Z and travoprost using a newly developed 
electrophysiological method. 
The cornea is generally recognized as the major route of ocular penetration for topically instilled 
drugs. It is composed of five layers, which include the epithelium, Bowman’s membrane, stroma, 
Descemet’s membrane, and the endothelium. Among these five layers, the barrier function that 
protects against foreign matter primarily depends upon the epithelium, which is composed of 
superficial cells, wing cells, and basal cells. Superficial cells and the tight junctions that are found 
between them play a major role in the epithelial barrier function.25, 26 TER can be mathematically 
described as follows: TER = Rtj × (Ra + Rb) / (Rtj + Ra + Rb). Apical and basolateral cell membrane 
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electrical resistances are respectively represented as Ra, Rb, while the tight junctional electrical 
resistance is represented as Rtj. Corneal TER reflects the electrical resistances of the superficial cells 
and the tight junctions. In addition, TER is a highly sensitive electrophysiologic parameter that can 
be used to measure the epithelial barrier change, with lower corneal TER values indicative of the 
penetration of greater amounts of electrical current through the damaged superficial cells and tight 
junctions.8, 18, 27-32 
We have recently developed an in vivo corneal TER measurement system that makes it possible to 
measure corneal changes both continuously and quantitatively within only a few seconds.18 The 
ability to evaluate eyedrop-induced corneal toxicity over a short period of time is invaluable, as 
normally tears dilute the eyedrops immediately after instillation.33 By using this method, we 
determined that the TER of the cornea of normal live rabbits was 701.6  43.1 ·cm2, which is 
considered to be an adequate value when compared to previous reports that have measured the 
corneal TER.18,19,28-30 After exposure to travoprost Z, which uses sofZia as the preservative system, 
TER exhibited almost the same results as those of the negative control, HBSS. This suggests that 
travoprost Z does not cause acute corneal barrier dysfunction. On the other hand, 0.015% BAC 
caused a dramatic reduction of TER. Our previous experiments have indicated that routine clinical 
concentrations (0.005%-0.02%) of BAC can cause an intense concentration-dependent decrease in 
the TER.19 Furthermore, it has been reported in a previous study that used isolated rabbit cornea that 
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commercial eyedrops containing BAC resulted in a lowering of the TER.32 However, when there was 
exposure to travoprost that contained 0.015% BAC, no significant changes were noted in the TER. 
The finding that travoprost, similar to travoprost Z, maintained the pre-exposure TER values was 
totally unexpected. Therefore, we believe that valuable information could potentially be discovered 
by more closely examining the mechanism used by travoprost to inhibit the BAC-induced corneal 
barrier dysfunction. Thus, we performed further experiments that electrophysiologically examined 
the influence of the travoprost additives on BAC. 
The additives contained within the travoprost solution include EDTA, boric acid, mannitol, 
trometamol, HCO-40, and BAC. While there was no suppression of the BAC-induced TER decrease 
for EDTA, boric acid, mannitol, and trometamol, HCO-40 was found to remarkably prevent the 
BAC-induced corneal barrier dysfunction during the acute phase. Both SEM and a cytotoxicity assay 
confirmed these results. SEM-based histological analyses of the control corneas indicated that the 
appearance of the superficial layer was good and that there was clear damage of the corneal 
epithelium in corneas exposed to 0.02% BAC. These corneal epithelial images are consistent with 
previously published reports.4-7,18,34 The results of the NRCE cell viability assay after exposure to 
travoprost additives with or without BAC were similar to the results of the TER measurements. 
When HCO-40 was added to BAC, remarkable improvement of the BAC-induced corneal epithelial 
toxicity was noted for both the SEM and cytotoxicity assay results. This supports our belief that 
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HCO-40 provides protection against the BAC-induced corneal toxicity that occurs with travoprost. 
Protective effects against BAC-induced ocular toxicity have also been reported for hyaluronic 
acid.35-37 These studies also postulated that the mechanism of this protective effect could possibly be 
related to the ionic attraction between the positive charge of BAC and the negative charge of the 
hyaluronic acid, with the ionic complexes able to neutralize the toxic effect caused by the cationic 
charge of BAC. It was also suggested that part of the action might be caused by the penetration and 
subsequent dispersal of BAC within the sponge-like domain of the hyaluronic acid. 
HCO-40 and BAC, however, are nonionic and cationic surfactants, respectively. These agents 
consist of two components that include a large nonpolar hydrocarbon chain that attracts hydrophobic 
substances along with a hydrophilic group that is strongly attracted by water molecules. Based on 
this, the protective mechanism of HCO-40 should differ from hyaluronic acid, which is composed of 
disaccharides. In order to elucidate this modulation mechanism, we decided to measure the particle 
size and zeta potential of BAC alone followed by the measurement of HCO-40 in the absence and 
presence of BAC. The particle size and zeta potential of 0.02% BAC were not detectable, as 0.02% 
BAC was much lower than the required 5 mM (approximately 0.2%) critical micelle concentration 
(CMC).38 On the other hand, measurement of 1% HCO-40 found there was a 25.7-nm mean particle 
size that had a slightly negative surface charge. Furthermore, the addition of 0.02% BAC, which had 
a cationic charge, induced a reduction of the particle size and modified the surface charge from 
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negative to positive. Theses results indicate that the micelles of the 1% HCO-40 with 0.02% BAC 
have a coating layer of BAC molecules. When the BAC molecules combine with the micelles, there 
is strong hydrophobic and ionic bonding that reduces the particle size. Therefore, these findings 
suggest that the protective effect of HCO-40 is induced by an interaction between HCO-40 and BAC. 
If so, then a decrease in the amount of free BAC molecules that attach to the corneal epithelium 
should be observed. To definitively elucidate the details of the protective mechanism of HCO-40, 
further studies will be necessary. Furthermore, this study only examined the corneal epithelial 
change that occurred in animal corneas during the acute phase. It should be noted that the current 
study was not able to sufficiently clarify whether chronic corneal epithelial impairment occurs after 
long time usage of these drugs in humans. 
In general, ophthalmic formulations that contain high concentrations of the preservative BAC are 
associated with corneal toxicity. However, results from the present study indicate that BAC 
concentrations listed on a label do not always reflect whether there will be an eyedrop-caused acute 
corneal toxicity. When considering this potential toxicity, it is also necessary to examine the possible 
interaction of BAC with the other ophthalmic additives. In conclusion, our results demonstrated that 
travoprost preserved with either sofZia or with 0.015% BAC did not cause acute cornel barrier 
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Figures / Figure legends 
FIG. 1. Corneal TER changes after a 60-s exposure to travoprost Z (without BAC), travoprost 
(containing 0.015% BAC), or 0.015% BAC. Data represent the percentage to pre-exposure TER 
value (100%). Each value is the mean  S.E. (n = 4-5). ** p < 0.01 as compared with HBSS, 

























































































FIG. 2.  Corneal TER changes after a 60-s exposure to travoprost additives in the absence (A) or 
presence of 0.02% BAC (B). Data represent the percentage of the pre-exposure TER value (100%). 
HBSS served as the negative control while BAC served as the positive control. Each value is the 
mean  S.E. (n = 3-4). **p < 0.01 as compared with BAC. ##p < 0.01 as compared with BAC, 







FIG. 3.  Scanning electron microscopy images of the corneal epithelium after a 60-s corneal 
exposure to HBSS. Magnification: 300 (A), 2000 (B), and 12,000 (C). Images indicate that the 







FIG. 4.  Scanning electron microscopy images of the corneal epithelium after a 60-s corneal 
exposure to 0.02% BAC. Magnification: 300 (A), 2000 (B), and 12,000 (C). Arrows indicate 
detaching (a) and wrinkling (b) of the superficial cells and dissociations between the cells (c). 







FIG. 5.  Scanning electron microscopy images of the corneal epithelium after a 60-s corneal 
exposure to 0.02% BAC with 1% HCO-40. Magnification: 300 (A), 2000 (B), and 12,000 (C). 








FIG. 6.  Cytotoxicity assay of travoprost additives to NRCE cells in the absence (A) or presence of 
0.02% BAC (B). NRCE cells were exposed to each test solution for 60 s. BAC was used as the 
positive control. Data represent the percentage of the untreated cells (control). Each value is the 
mean  S.E. (n = 6). *p < 0.05, **p < 0.01 as compared with BAC. ##p < 0.01 as compared with 







TABLE 1.  Physicochemical properties of BAC, HCO-40, and HCO-40 with BAC 
Each value is the mean  S.E. (n = 3). N.D.: not detected. 
**p < 0.01, as compared with 1% HCO-40. 
